Form 4: Forbion Funds Reduce Stake in NewAmsterdam Pharma Through Pre-Planned Sales

Forbion Capital funds executed pre-planned sales of NewAmsterdam Pharma shares, reducing their holdings slightly.

Summary

• ForGrowth NAP B.V., along with related Forbion entities, sold shares of NewAmsterdam Pharma (NAMS) on November 13th and 14th, 2024.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 28, 2024.
• On November 13th, 1,066 shares were sold at a weighted average price of $25.0043.
• On November 14th, 9,832 shares were sold at a weighted average price of $25.0057.
• The sales were executed on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. and Forbion Capital Fund IV Cooperatief U.A.
• Following these transactions, ForGrowth NAP B.V. still beneficially owns 11,820,563 ordinary shares of NewAmsterdam Pharma.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-planned trading plan. There is no indication of significant positive or negative sentiment. The sales are minor in the context of the overall holdings.

Positives

• The sales were pre-planned under a Rule 10b5-1 trading plan, indicating an orderly and transparent process.
• The weighted average sale price was consistent across both days, suggesting stable market conditions.

Negatives

• The sales represent a slight reduction in the holdings of a major shareholder, which could be perceived negatively by some investors.

Risks

• Continued sales by major shareholders could put downward pressure on the stock price.
• The market may react negatively to the reduction in holdings by Forbion funds.

Industry Context

This transaction is a routine disclosure of share sales by a major institutional investor and is not unusual in the biotech sector. It is common for funds to periodically adjust their holdings.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common mechanism for insiders and major shareholders to sell shares in a pre-planned and transparent manner, aligning with industry best practices.
• The reported sales are relatively small compared to the overall holdings of ForGrowth NAP B.V., which is typical for institutional investors managing large portfolios.
• Similar transactions are frequently observed in other publicly traded biotech companies, such as those by venture capital funds in companies like BioNTech or Moderna.

Stakeholder Impact

• The share sales may have a minor impact on the stock price, potentially affecting shareholders.
• The transactions do not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

NewAmsterdam Pharma, NAMS, Forbion Capital, Share Sale, Rule 10b5-1, Trading Plan, Institutional Investor, Shareholder